Nuvectis Pharma, Inc.
NVCT
$9.28
-$0.21-2.21%
| Weiss Ratings | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.37 | |||
| Price History | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 33.91% | |||
| 30-Day Total Return | 36.47% | |||
| 60-Day Total Return | 81.60% | |||
| 90-Day Total Return | 47.07% | |||
| Year to Date Total Return | 72.17% | |||
| 1-Year Total Return | -11.20% | |||
| 2-Year Total Return | -25.46% | |||
| 3-Year Total Return | 18.52% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -20.19% | |||
| 52-Week Low % Change | 113.74% | |||
| Price | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $11.89 | |||
| 52-Week Low Price | $4.44 | |||
| 52-Week Low Price (Date) | Dec 20, 2024 | |||
| 52-Week High Price (Date) | Mar 18, 2024 | |||
| Valuation | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 221.99M | |||
| Enterprise Value | 203.45M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.11 | |||
| Earnings Per Share Growth | -22.34% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 19.05 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $9.28 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -10.25 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 17.76M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 201 614 3150 | |||
| Address | 1 Bridge Plaza Fort Lee, NJ 07024 | |||
| Website | www.nuvectis.com | |||
| Country | United States | |||
| Year Founded | 2020 | |||
| Profitability | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -65.65% | |||
| Return on Equity | -- | |||
| Income Statement | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -19.85M | |||
| Net Income (TTM) | -19.00M | |||
| Net Income Avl. to Common (TTM) | -19.00M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 5.65% | |||
| EPS Diluted (TTM) | -1.11 | |||
| EPS Diluted Growth (Q YOY) | 13.92% | |||
| Balance Sheet | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 18.53M | |||
| Cash Per Share (Q) | $1.04 | |||
| Total Current Assets (Q) | 18.61M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 9.71M | |||
| Current Ratio (Q) | 2.092 | |||
| Book Value Per Share (Q) | $0.50 | |||
| Total Assets (Q) | 18.61M | |||
| Total Current Liabilities (Q) | 8.89M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 8.89M | |||
| Total Common Equity (Q) | 9.71M | |||
| Cash Flow | NVCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 11.65M | |||
| Net Change in Cash (TTM) | -593.00K | |||
| Levered Free Cash Flow (TTM) | -6.93M | |||
| Cash from Operations (TTM) | -12.25M | |||
